The subsequent finding that GDF-15 is primarily responsible for the loss of appetite, whereas loss of muscle mass depends more on GDF-11 (43), may, however, limit the usefulness of anti-GDF-15 (mono)therapy in cancer patients with muscle wasting syndrome. Here, GDF15 is linked to cancer.